Susan Bobulsky, serving as Chief Commercial Officer and MRD at Adaptive Biotechnologies Corp (NASDAQ: ADPT), executed a sale of company stock on July 1, 2026, as detailed in a recent Form 4 filing. The transaction involved the disposal of 487 shares of common stock at a price point of $22.00 per share, resulting in a total transaction value of $10,714. Following the completion of this sale, Bobulsky's direct holdings in Adaptive Biotechnologies common stock stand at 406,288 shares.
The timing of this transaction is notable given the recent performance of ADPT shares. The stock has been trading near its 52-week high of $22.80, reflecting an 82% return over the preceding year. According to analysis from InvestingPro, ADPT appears to be trading in overvalued territory at current levels, with the Relative Strength Index (RSI) indicating overbought conditions. This assessment is one of several ProTips available to subscribers analyzing the stock.
The sale was conducted pursuant to a Rule 10b5-1 trading plan that Bobulsky adopted on December 16, 2025. This pre-arranged plan allows for the sale of securities regardless of subsequent price movements, providing a structured mechanism for executive transactions.
In parallel with the insider activity, Adaptive Biotechnologies reported financial results for the first quarter of 2026 that significantly exceeded market expectations. The company achieved revenue of $70.9 million, surpassing analyst forecasts of $60.89 million by approximately 16.4%. This strong performance was primarily attributed to the expansion of its Minimal Residual Disease (MRD) business.
Adaptive Biotechnologies has also announced plans to raise capital through a private placement of $250 million in convertible senior notes due in 2031, targeting qualified institutional buyers. The company retains an option for initial purchasers to acquire an additional $37.5 million in notes. In a related strategic development, Adaptive Biotechnologies intends to separate its MRD and Immune Medicine businesses. The company expects to determine its preferred separation path by the end of 2026.
Following the announcement of the business split and the upsized convertible notes offering, BTIG reiterated its Buy rating on ADPT, maintaining a price target of $22.00. These developments collectively highlight Adaptive Biotechnologies' efforts to optimize its financial structure and focus on distinct business segments.